These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Ethnic differences in atrial fibrillation among patients with heart failure in Asia. Tan ESJ; Goh V; Santema BT; Tay WT; Teng TK; Yap J; Tromp J; Hung CL; Chopra V; Anand I; MacDonald MR; Ling LH; ; Van Gelder IC; Rienstra M; Voors AA; Richards AM; Lam CSP ESC Heart Fail; 2020 Aug; 7(4):1419-1429. PubMed ID: 32383559 [TBL] [Abstract][Full Text] [Related]
48. Beta Adrenergic Blocker Use in Patients With Chronic Obstructive Pulmonary Disease and Concurrent Chronic Heart Failure With a Low Ejection Fraction. Mtisi TF; Frishman WH Cardiol Rev; 2020; 28(1):20-25. PubMed ID: 31804289 [TBL] [Abstract][Full Text] [Related]
49. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. McMurray J; Ostergren J; Pfeffer M; Swedberg K; Granger C; Yusuf S; Held P; Michelson E; Olofsson B; Eur J Heart Fail; 2003 Jun; 5(3):261-70. PubMed ID: 12798823 [TBL] [Abstract][Full Text] [Related]
50. Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. Hamdani N; Paulus WJ; van Heerebeek L; Borbély A; Boontje NM; Zuidwijk MJ; Bronzwaer JG; Simonides WS; Niessen HW; Stienen GJ; van der Velden J Eur Heart J; 2009 Aug; 30(15):1863-72. PubMed ID: 19487234 [TBL] [Abstract][Full Text] [Related]
51. Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Puente-Maestu L; Calle M; Ortega-González A; Fuster A; González C; Márquez-Martín E; Marcos-Rodriguez PJ; Calero C; Rodríguez-Hermosa JL; Malo de Molina R; Aburto M; Sobradillo P; Alcázar B; Tirado-Conde G; Respir Med; 2014 May; 108(5):737-44. PubMed ID: 24635914 [TBL] [Abstract][Full Text] [Related]
52. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China]. Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275 [No Abstract] [Full Text] [Related]
53. Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. Cooper LB; Yap J; Tay WT; Teng TK; MacDonald M; Anand IS; Sharma A; O'Connor CM; Kraus WE; Mentz RJ; Lam CS; Eur J Heart Fail; 2018 Sep; 20(9):1281-1289. PubMed ID: 29943890 [TBL] [Abstract][Full Text] [Related]
54. Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction. Loop MS; van Dyke MK; Chen L; Safford MM; Kilgore ML; Brown TM; Durant RW; Levitan EB J Card Fail; 2019 May; 25(5):343-351. PubMed ID: 30339796 [TBL] [Abstract][Full Text] [Related]
55. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study. Takada T; Sakata Y; Miyata S; Takahashi J; Nochioka K; Miura M; Tadaki S; Shimokawa H; Eur J Heart Fail; 2014 Mar; 16(3):309-16. PubMed ID: 24464774 [TBL] [Abstract][Full Text] [Related]
56. Prognostic influence of prior chronic obstructive pulmonary disease in patients admitted for their first episode of acute heart failure. Londoño KL; Formiga F; Chivite D; Moreno-Gonzalez R; Migone De Amicis M; Corbella X Intern Emerg Med; 2018 Apr; 13(3):351-357. PubMed ID: 29508227 [TBL] [Abstract][Full Text] [Related]
57. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. Mentz RJ; Schmidt PH; Kwasny MJ; Ambrosy AP; O'Connor CM; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Gheorghiade M J Card Fail; 2012 Jul; 18(7):515-23. PubMed ID: 22748484 [TBL] [Abstract][Full Text] [Related]
58. β-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease. Rutten FH Future Cardiol; 2011 Jan; 7(1):43-53. PubMed ID: 21174509 [TBL] [Abstract][Full Text] [Related]
59. The role of beta-blockers in the management of chronic obstructive pulmonary disease. Leitao Filho FS; Alotaibi NM; Yamasaki K; Ngan DA; Sin DD Expert Rev Respir Med; 2018 Feb; 12(2):125-135. PubMed ID: 29258360 [TBL] [Abstract][Full Text] [Related]
60. Prognosis of heart failure with preserved ejection fraction treated with β-blockers: A propensity matched study in the community. Ruiz G; Andrey JL; Puerto JL; Escobar MA; Romero SP; Aranda R; Pedrosa MJ; Gomez F Int J Cardiol; 2016 Nov; 222():594-602. PubMed ID: 27513657 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]